Gilead Sciences, Inc. (GILD) Return on Invested Capital (ROIC): 21.53%
Is Gilead Sciences, Inc.’s return on invested capital (ROIC) high or low?
Gilead Sciences, Inc.'s return on invested capital (ROIC) of 21.53% is 117% above its 5-year average of 9.92%, near the high end of its 5-year range (0.36%–21.53%).
The return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD) is 21.53% as of Wednesday, June 10, 2026. It is above its 12-month average by 80.24% (11.95%).
GILD Return on Invested Capital (ROIC) Chart
GILD Average Return on Invested Capital (ROIC) Chart
GILD Current vs Average Return on Invested Capital (ROIC) Chart
GILD Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
21.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
11.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
11.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
9.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
14.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
17.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
18.18%
CURRENT VS TTM AVG
+80.24%
CURRENT VS 3Y AVG
+85.88%
CURRENT VS 5Y AVG
+117.00%
CURRENT VS 10Y AVG
+49.83%
CURRENT VS 15Y AVG
+21.77%
CURRENT VS 20Y AVG
+18.43%
GILD Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | — | 21.53% | 11.95% | 11.58% | 9.92% |
| Abbott Laboratories (ABT) | $154.66B | 8.43% | 9.16% | 9.70% | 9.86% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE) | $146.36B | 8.84% | 9.06% | 10.60% | 10.43% |
| Danaher Corporation (DHR) | $130.25B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS) | $125.16B | 4.72% | 4.17% | 4.46% | 4.93% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 7.58% | 7.80% | 8.16% | 9.10% |
| Amgen Inc. (AMGN) | $183.75B | 13.16% | 11.04% | 11.80% | 12.80% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 13.90% | 13.75% | 11.92% | 10.17% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 18.12% | 10.38% | 14.75% | 17.51% |
Capital Efficiency
ROIC
21.5%
ROE
39.2%
Gilead Sciences, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The return on invested capital (ROIC) for GILD stock is 21.53%.
- Is Gilead Sciences, Inc.'s return on invested capital (ROIC) high or low?
- Gilead Sciences, Inc.'s return on invested capital (ROIC) of 21.53% is 117% above its 5-year average of 9.92%, near the high end of its 5-year range (0.36%–21.53%).
- What is the TTM average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The TTM average return on invested capital (ROIC) for GILD stock is 11.95%.
- What is the 3Y average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The 3Y average return on invested capital (ROIC) for GILD stock is 11.58%.
- What is the 5Y average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The 5Y average return on invested capital (ROIC) for GILD stock is 9.92%.
- What is the 10Y average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The 10Y average return on invested capital (ROIC) for GILD stock is 14.37%.
- What is the 15Y average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The 15Y average return on invested capital (ROIC) for GILD stock is 17.68%.
- What is the 20Y average return on invested capital (ROIC) for Gilead Sciences, Inc. (GILD)?
- The 20Y average return on invested capital (ROIC) for GILD stock is 18.18%.
Gilead Sciences, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 21.53% |
| 2024-12-31 | 2.36% |
| 2023-12-31 | 11.82% |
| 2022-12-31 | 10.62% |
| 2021-12-31 | 12.84% |
| 2020-12-31 | 0.36% |
| 2019-12-31 | 7.89% |
| 2018-12-31 | 10.28% |
| 2017-12-31 | 7.90% |
| 2016-12-31 | 29.13% |
| 2015-12-31 | 43.34% |
| 2014-12-31 | 42.17% |
| 2013-12-31 | 17.42% |
| 2012-12-31 | 15.73% |
| 2011-12-31 | 19.57% |
| 2010-12-31 | 29.93% |
| 2009-12-31 | 33.76% |
| 2008-12-31 | 34.51% |
| 2007-12-31 | 30.20% |
| 2006-12-31 | -22.71% |
| 2005-12-31 | 23.11% |
| 2004-12-31 | 22.57% |
| 2003-12-31 | -4.98% |
| 2002-12-31 | 6.72% |
| 2001-12-31 | -15.64% |
| 2000-12-31 | -8.40% |
| 1999-12-31 | -13.18% |
| 1998-12-31 | -17.99% |
| 1997-12-31 | -22.49% |
| 1996-12-31 | 0.00% |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day